United States Personalized Medicine Market - Genomic Trends & Forecast 2026-2034

United States Personalized Medicine Market Size and Forecast 2026-2034

United States Personalized Medicine Market is expected to reach US$ 327.97 billion by 2034 from US$ 181.12 billion in 2025, with a CAGR of 6.82% from 2026 to 2034. The United States personalized medicine market is expected to expand significantly during the forecast period, supported by advances in genomics, precision diagnostics, targeted therapies, and increasing emphasis on individualized patient care.

United States Personalized Medicine Industry Overview

The United States personalized medicine market represents one of the most advanced segments of the healthcare industry, driven by rapid progress in genetic science, molecular diagnostics, and precision healthcare technologies. Personalized medicine focuses on tailoring medical treatments, preventive strategies, and healthcare interventions according to an individual's genetic profile, lifestyle factors, and disease characteristics. This approach enables healthcare providers to deliver more targeted therapies, improve treatment outcomes, and minimize adverse drug reactions. Personalized medicine is increasingly being applied across various therapeutic areas, including oncology, cardiovascular diseases, rare genetic disorders, neurology, immunology, and infectious diseases. As healthcare systems continue transitioning toward patient-centered care, the demand for precision-based treatment solutions is growing across the United States.

The United States precision medicine market is primarily driven by the widespread prevalence of chronic diseases, including cancer and cardiovascular conditions. According to the U.S. Food & Drug Administration, seven of the ten leading causes of death in the U.S. are common chronic diseases (CCDs), with diet-related illnesses such as cardiovascular disease, diabetes, obesity, and certain cancers contributing significantly. The U.S. ranks behind 42 countries in diet-related disease rates, while 28 million Americans continue to smoke, increasing the need for targeted therapeutic interventions. Ongoing advancements in genomics and bioinformatics are enhancing personalized therapy development. Additionally, growing pharmaceutical investments in precision medicine research, supportive government initiatives, and the integration of AI and big data analytics are improving patient profiling, treatment customization, and overall market adoption.

The increasing availability of direct-to-consumer genetic testing services is enhancing patient awareness and engagement, acting as a significant growth-inducing factor for the U.S. precision medicine market. Strategic partnerships between research centers and healthcare providers are also accelerating the translation of research into clinical practice. For instance, on August 26, 2024, Care Access announced a multimillion-dollar agreement with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to strengthen pandemic preparedness. The initiative will expand Care Access’s decentralized clinical trial network by adding up to 150 community-based clinicians across 30 regions, underserved community organizations, and nationwide long-term care providers. Growing demand to reduce adverse drug reactions and improve treatment effectiveness is further supporting precision medicine adoption.

Growth Drivers for the United States Personalized Medicine Market

Growing Use of NGS

Next-generation sequencing (NGS), which offers faster and less expensive genetic profiling than conventional technology, is increasing the size of the precision medicine market in the United States. For example, on October 17, 2024, Illumina unveiled the MiSeq i100 Series, their newest benchtop sequencing equipment intended to enhance laboratory next-generation sequencing (NGS) capabilities. Flexible output capabilities are offered by these systems; the MiSeq i100 Plus, which is expected to be available worldwide in 2025, can generate up to 100 million single end reads each run. Because of this, NGS technology has been quite successful in identifying biomarkers and uncommon mutations, which has greatly accelerated the research process for developing individualized treatment plans. This makes it easier to tailor cancer treatments to each patient's unique genetic profile, especially in oncology. Precision medicine in the US is being greatly advanced by the high market demand for NGS in clinical diagnostics and research, which is expanding market potential and supporting the trends and growth observed across healthcare sectors.

Growing Demand for Targeted and Effective Therapies

Patients and healthcare providers are increasingly seeking treatment approaches that deliver better outcomes while minimizing side effects. Personalized medicine addresses this need by matching therapies to the specific biological characteristics of individual patients. Targeted treatments can improve therapeutic effectiveness by focusing on the underlying mechanisms of disease rather than relying on generalized treatment approaches. This is particularly important in complex conditions such as cancer, where genetic differences can significantly influence treatment response. Pharmaceutical companies are developing precision therapies supported by companion diagnostics to ensure appropriate patient selection. The growing preference for more effective and individualized treatment strategies continues driving demand for personalized medicine solutions throughout the United States.

Increasing Investment in Precision Healthcare Research

Substantial investment in precision healthcare research is contributing significantly to the growth of the personalized medicine market. Government agencies, academic institutions, biotechnology firms, and pharmaceutical companies are actively funding research programs focused on genomics, biomarker discovery, and targeted therapeutics. Collaborative initiatives are accelerating the translation of scientific discoveries into clinical applications. Research efforts aimed at understanding genetic influences on disease susceptibility and treatment response are creating new opportunities for personalized healthcare solutions. The availability of advanced research infrastructure and large-scale patient data resources further supports innovation. These investments continue expanding the scientific foundation of personalized medicine while fostering the development of new diagnostic and therapeutic technologies.

Challenges in the United States Personalized Medicine Market

High Costs of Genetic Testing and Precision Therapies

One of the primary challenges facing the personalized medicine market is the cost associated with advanced diagnostic testing and targeted treatments. Genetic sequencing, molecular profiling, and precision therapies often require sophisticated technologies and specialized expertise, contributing to higher healthcare expenditures. Although technological advancements are improving efficiency, affordability remains a concern for healthcare providers, patients, and payers. Access to personalized medicine services may vary depending on insurance coverage and healthcare resources. Balancing innovation with cost-effectiveness is essential for ensuring broader adoption of personalized healthcare approaches. Addressing economic barriers remains an important priority for industry stakeholders seeking to expand access to precision medicine.

Data Privacy and Ethical Considerations

Personalized medicine relies heavily on the collection, storage, and analysis of genetic and health-related information, creating important privacy and ethical challenges. Protecting sensitive patient data while enabling scientific research and clinical innovation requires robust security measures and regulatory oversight. Concerns regarding data ownership, consent, and potential misuse of genetic information continue to influence public perception and policy discussions. Healthcare organizations and technology providers must ensure compliance with privacy regulations while maintaining patient trust. Ethical considerations surrounding genetic testing, predictive health information, and data sharing require careful management. Successfully addressing these issues is essential for the sustainable growth of the personalized medicine market.

California Personalized Medicine Market

California represents one of the leading personalized medicine markets in the United States due to its concentration of biotechnology companies, research institutions, and advanced healthcare organizations. The state serves as a hub for genomic research, precision diagnostics, and targeted therapeutic development. Healthcare providers increasingly incorporate genetic testing and molecular profiling into clinical practice to improve patient outcomes. Strong collaboration between academic institutions, technology companies, and pharmaceutical organizations accelerates innovation and commercialization of personalized medicine solutions. The state's robust investment environment and highly skilled workforce further support market development. California's leadership in life sciences and healthcare innovation positions it as a major contributor to the growth of personalized medicine nationwide.

The US state of California announced in January 2024 that the city of Bakersfield, the Kern Venture Group, and BIOS Health will work together to construct a precision medicine facility. The facility will undoubtedly serve as a hub for research and development as well as brain clinical trials utilizing BIOS' adaptive dose technology.

Texas Personalized Medicine Market

Texas is emerging as an important market for personalized medicine, supported by its expanding healthcare infrastructure, research capabilities, and growing biotechnology sector. Major medical centers and research institutions are actively involved in genomic medicine, precision oncology, and translational research initiatives. Healthcare providers increasingly utilize personalized treatment approaches to improve disease management and patient care. The state's diverse population also provides valuable opportunities for genetic research and clinical studies. Investments in biotechnology innovation and healthcare modernization continue strengthening the adoption of precision medicine technologies. These factors contribute to Texas's growing significance within the United States personalized medicine market.

New York Personalized Medicine Market

New York plays a prominent role in the personalized medicine market due to its world-class healthcare institutions, research organizations, and pharmaceutical industry presence. The state has become a center for innovation in genomics, molecular diagnostics, and precision therapeutics. Hospitals and healthcare providers increasingly integrate genetic testing and individualized treatment planning into routine clinical care. Research collaborations between academic centers and industry participants support the development of new personalized medicine applications. Growing patient awareness regarding preventive healthcare and targeted therapies further drives market demand. New York continues to contribute significantly to advancements in precision healthcare and personalized treatment strategies.

Florida Personalized Medicine Market

Florida's personalized medicine market is expanding steadily as healthcare providers adopt advanced diagnostic technologies and precision treatment approaches. The state's growing population, strong healthcare sector, and increasing prevalence of chronic diseases support demand for individualized medical care. Research institutions and healthcare organizations are investing in genomic medicine, molecular diagnostics, and patient-centered treatment models. The growing elderly population further increases the need for targeted healthcare solutions that improve treatment effectiveness and quality of life. Advances in healthcare technology and rising awareness of precision medicine benefits continue encouraging adoption throughout the state. These factors position Florida as an increasingly important market within the United States personalized medicine industry.

Recent Developments in United States Personalized Medicine Market

• The IMS Open-Source Consortium was established by Tempus AI, Inc. in June 2026 with the goal of standardizing digital pathology through partnerships with top academic medical institutions, such as YNHH and MSK. Through developments in digital pathology and artificial intelligence, the group hopes to improve clinical procedures.
• At the SelectUSA Investment Summit in Washington, D.C. in May 2026, CTIBIOTECH introduced CTIBIOTECH USA, its North American subsidiary. In order to promote personalized predictive medicine, the subsidiary, which has its headquarters in Philadelphia's Cellicon Valley, will supply the pharmaceutical, biomedical, and dermatocosmetics industries with patented human cell and tissue bioassays and New Approach Methods.

Research Methodology of United States Personalized Medicine Market

The United States Personalized Medicine Market had been estimated through a combination of bottom-up and top-down approaches, secondary research, company-level analysis, product-level assessment, and data triangulation. The methodology had considered personalized diagnostics, genomic testing, targeted therapeutics, companion diagnostics, pharmacogenomics, personalized cancer treatment, and other precision-medicine applications.

1. Market Definition and Scope

• The market had first been defined to establish which products, services, and applications had been included in the estimation.
• The United States Personalized Medicine Market had been considered to include revenues generated from healthcare products and services that had used an individual's:
• Genetic information
• Genomic information
• Molecular information
• Clinical information
• Other patient-specific information
• These products and services had been used to support:
• Disease prevention
• Disease diagnosis
• Treatment selection
• Treatment monitoring
• Therapy optimization
• The market scope had included relevant personalized diagnostics, genomic testing, targeted therapies, companion diagnostics, pharmacogenomics, precision oncology, and related services.

2. Secondary Research

• Extensive secondary research had been conducted to establish the underlying market variables.
• Information had been collected from:
• U.S. government healthcare databases
• Regulatory agencies
• National health organizations
• Medical associations
• Pharmaceutical companies
• Biotechnology companies
• Diagnostic companies
• Genomic testing providers
• Clinical laboratories
• Company annual reports
• Investor presentations
• Product documentation
• Clinical-trial databases
• Scientific publications
• Healthcare industry publications
• The research had focused on determining:
• Number of relevant tests
• Number of personalized therapies
• Companion diagnostic utilization
• Sequencing services
• Patients receiving personalized treatments
• Healthcare facilities using personalized medicine
• Revenue generated by major market participants
• Secondary research had provided the foundation for both demand-side and supply-side market estimation.

3. Bottom-Up Market Estimation

• A bottom-up approach had been used to calculate the market by individual product, service, application, and company.
• For diagnostic and service-based applications, the calculation had followed: Number of Personalized Medicine Tests/Services/Products × Average Revenue per Unit = Market Revenue
• For therapeutic applications, the calculation had been adjusted to: Number of Patients Receiving Personalized Therapies × Average Revenue per Treatment = Personalized Medicine Revenue
• Separate calculations had been performed for:
• Personalized diagnostics
• Genetic testing
• Genomic testing
• Molecular diagnostics
• Targeted therapeutics
• Companion diagnostics
• Sequencing
• Personalized medicine services
• This segmentation had prevented high-value targeted therapies from being averaged together with relatively low-priced genetic tests and laboratory services.

4. Company-Level Revenue Analysis

• Major personalized medicine companies operating in the United States had been identified and analyzed.
• Companies had been grouped according to their principal activities, including:
• Genomic testing
• Molecular diagnostics
• Companion diagnostics
• Sequencing
• Targeted therapeutics
• Bioinformatics
• Precision oncology
• Publicly reported company revenues had been reviewed. The proportion of revenue attributable to personalized medicine had then been estimated.
• Where companies had generated revenue from both personalized and conventional healthcare products, only the relevant personalized-medicine portion had been incorporated. Company-level revenue estimates had subsequently been reconciled with product- and patient-level calculations.

5. Product-Level Validation

• Individual products and services had been reviewed to validate company-level revenue estimates.
• The assessment had considered:
• Product launches
• Regulatory approvals
• Indications
• Target patient populations
• Testing requirements
• Pricing
• Adoption
• Geographic availability
• Annual revenue
• Product-level information had been particularly useful when companies had not separately disclosed their personalized medicine revenues.
• The analysis had linked individual products to their corresponding applications, patient populations, and revenue contributions.

6. Reimbursement-Based Estimation

• A reimbursement-based approach had been used to validate diagnostic market calculations.
• The analysis had considered:
• Medicare reimbursement
• Commercial insurance reimbursement
• Medicaid reimbursement
• Laboratory payment levels
• Coverage policies
• Patient out-of-pocket payments
• The number of reimbursed tests had been multiplied by the estimated reimbursement value: Reimbursed Test Volume × Average Reimbursement per Test = Estimated Diagnostic Revenue
• Reimbursement rates had been adjusted where commercial payer reimbursement had differed materially from public-payer reimbursement.
• Reimbursement analysis had provided an additional validation layer for diagnostic and laboratory-based personalized medicine revenues.

7. Patient-Based Market Estimation

• A patient-based methodology had been used for personalized treatment applications.
• The number of patients eligible for personalized medicine had been estimated using disease prevalence and diagnosis data.
• The calculation had followed: Disease Population × Diagnosed Population × Biomarker Testing Rate × Treatment Adoption Rate × Average Revenue per Patient
• This approach had been particularly relevant to:
• Oncology
• Rare diseases
• Genetic disorders
• Patient eligibility had been adjusted based on the availability of biomarker testing, treatment suitability, clinical adoption, and access to personalized therapies.
• The resulting patient-based estimate had been compared with company-level and product-level revenue calculations.

8. Top-Down Market Estimation

• A top-down approach had been applied to validate the bottom-up estimate.
• Broader U.S. markets had been assessed, including:
• Healthcare
• Diagnostics
• Genomics
• Biotechnology
• Targeted therapies
• The portion associated with personalized medicine had then been estimated based on:
• Personalized medicine adoption
• Genetic testing penetration
• Molecular diagnostic utilization
• Targeted therapy adoption
• Companion diagnostic use
• Precision oncology activity
• The calculation had followed: Relevant U.S. Healthcare/Diagnostics/Therapeutics Market × Personalized Medicine Share = Estimated Personalized Medicine Market
• The top-down result had then been compared with the detailed bottom-up calculation.
• Differences had been investigated through product, patient, pricing, and company-level assumptions.

9. Supply-Side Validation

• The supply side had been analyzed by examining the revenues and operations of companies involved in personalized medicine.
• Company information had been compared across:
• Genomic testing revenues
• Molecular diagnostic revenues
• Sequencing revenues
• Targeted therapy revenues
• Companion diagnostic revenues
• Precision medicine services
• The combined company-level assessment had been compared with the demand-side market estimate.
• This process had helped identify:
• Potential market omissions
• Overlapping revenue streams
• Double counting
• Differences between reported and estimated market contributions

10. Demand-Side Validation

• Market demand had been validated through the number of patients, tests, treatments, healthcare providers, and institutions using personalized medicine.
• The demand-side calculation had followed: Patient Population → Eligible Patients → Testing → Treatment Selection → Personalized Treatment → Revenue
• The patient and procedure volumes had been compared with available product utilization and company revenue information.
• This approach had provided a patient-centric perspective and had allowed the market estimate to be cross-checked against the supply-side calculation.

11. Avoiding Double Counting

• Particular attention had been given to avoiding double counting across diagnostic and therapeutic segments.
• For example, a patient undergoing genomic testing and subsequently receiving a targeted therapy could have generated revenue in both the diagnostic and therapeutic segments.
• These revenues had been treated as separate market components only where the market definition had included both categories.
• Revenues reported by pharmaceutical and diagnostic companies had also been reviewed to ensure that the same companion diagnostic revenue had not been counted twice through:
• Supplier-level calculations
• Product-level calculations
• Diagnostic market estimates
• The final market model had therefore been structured to maintain consistency across different revenue streams.

12. Forecast Estimation

• The validated historical market base had subsequently been used to forecast future market development.
• The forecast model had considered:
• Increasing genomic testing
• Expansion of precision oncology
• New targeted therapies
• Growth in companion diagnostics
• Expansion of pharmacogenomics
• Adoption of next-generation sequencing
• Growth in rare-disease diagnosis
• Increasing availability of biomarker-based treatments
• Advances in bioinformatics
• Increasing integration of genomic information into clinical decision-making
• Separate growth assumptions had been applied to:
• Personalized diagnostics
• Personalized therapeutics
• Personalized medicine services
• Forecast assumptions had been adjusted according to technology adoption, clinical utilization, regulatory developments, and treatment availability.

13. Data Triangulation

• The final United States Personalized Medicine Market estimate had been established through data triangulation using three major approaches.
• Bottom-up Approach: Test Volume/Patient Volume × Average Revenue
• Product, service, testing, and patient-level estimates had been aggregated to calculate market revenue.
• Top Down Approach: Relevant U.S. Healthcare Market × Personalized Medicine Share
• Broader healthcare, diagnostics, genomics, and targeted-therapy markets had been narrowed to the personalized medicine component.
• Supply-Side Approach: Company Revenues + Product-Level Assessment
• Company-reported revenues had been combined with product-level analysis to estimate the relevant personalized medicine contribution.
• The results from all approaches had been compared and reconciled.
• Significant differences had been investigated by reviewing:
• Patient population assumptions
• Testing penetration
• Treatment adoption
• Pricing
• Reimbursement
• Company revenue allocation
• Diagnostic versus therapeutic coverage
• Market definition

14. Final Market Calculation

The final United States Personalized Medicine Market estimate had been established through the following framework:

• U.S. Population → Relevant Disease & Patient Population → Diagnosed & Eligible Patients → Biomarker/Genomic Testing → Personalized Treatment Eligibility → Personalized Medicine Adoption → Estimated Tests/Patients/Treatments → Average Revenue per Test/Treatment → Product & Service-Level Revenue → Company-Level Revenue Aggregation → Bottom-Up Market Size → Top-Down Validation → Reimbursement & Demand-Side Validation → Supply-Side Validation → Data Triangulation → Final United States Personalized Medicine Market Size
• The final estimate had then been cross-checked against:
• Top-down market calculations
• Company-level revenues
• Patient-based estimates
• Reimbursement data
• Product-level calculations
• Diagnostic and therapeutic revenue estimates

Market Segmentations

Product

• Personalized Medicine Therapeutics
• Personalized Medicine Diagnostics
• Personalized Medical Care
• Personalized Nutrition and Wellness

Application

• Oncology
• Infectious disease
• Neurology or Psychiatry
• Cardiovascular
• Others

End User

• Hospitals
• Diagnostic Centers
• Research & Academic Institutes
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• GE Healthcare, Inc.
• Aadi Bioscience, Inc.
• Illumina, Inc.
• QIAGEN
• Eli Lilly and Company
• Takeda Pharmaceutical Company Ltd
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.